A political appointee inside HHS intervened to block approval of Sanofi's Tzield — a drug already on the market for type 1 diabetes — according to STAT News reporting on the agency's D.C. Diagnosis newsletter. The interference adds to a documented pattern of political pressure on FDA's scientific review process under the current administration.
The operative detail: this isn't a novel compound under scrutiny for safety unknowns. Tzield has an existing approval trail. A political layer inserting itself into that process isn't regulatory caution — it's a tell. Someone is running a play, and it isn't about protecting patients.
Who benefits from an unpredictable FDA? Anyone who wants the approval process to be a negotiating lever rather than a scientific one. Once that norm breaks, every pending approval becomes a pressure point. That's not a bug in this operation — it's the architecture.